Cancer/Tumor Profiling Market 2019 Scope Analysis and Competitive Landscape Assessment | Size, Share and Growth | Industry Overview By 2026
Cancer profiling is an advanced technique used to identify tumors more accurately, by determining genomic alteration, which supports to select appropriate therapy for the treatment of cancer. Moreover, this technique decreases the trial and error during the process in the diagnosis of cancer at various stages and provide more precise and accurate information about clinical outcomes of cancer. Laboratory test (blood and urine), biopsy, imaging test (X-ray, MRI, PET/CT, and ultrasound), nuclear medicine scan, and lumbar puncture, are some of the tests used to diagnose cancer which is unable to identify the exact cause of cancer in early stages.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/967
According to the World Health Organization (WHO), nearly 1 in 6 deaths occurs due to cancer and around 8.8 million people died from cancer worldwide in 2015. Increasing incidence and prevalence of different cancers among individuals augmented the demand for accurate diagnosis of cause in the early stage of cancer.
Introduction of cancer profiling over traditional cancer diagnostic procedure is expected to gain growth of the Cancer/Tumor profiling market
St. Jude Medical Center’s Crosson Cancer Institute has joined Caris’ Precision Oncology Alliance (POA) as its 17th member in 2017. POA is established by Caris Life Sciences to promote the appropriate use of the molecular tools in the diagnosis and treatment of cancer. The St. Jude Medical Center’s Crosson Cancer Institute will help Caris Life Sciences to develop standard and best practices to make cancer treatment more effective and precise by advancing the use of tumor profiling.
EpiVax Inc. launched EpiVax Oncology Inc., which is an approach for precision cancer immunotherapy in 2017. EpiVax used molecular profiling through Next-Generation Sequencing (NGS) to produce therapeutic vaccines for cancer.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/967
Personal Genome Diagnostics Inc. has introduced CancerSELECT 125 test for pan-cancer tumor profiling in 2016. CancerSELECT 125 identify tumor-specific functional sequence mutation in multiple cancer types with high accuracy.
Rising prevalence of cancer and growing demand for accurate diagnosis of cancer in the early stage is projected to fuel the growth of cancer profiling market
According to a report by American Cancer Society (ACS), in 2016, around 1,685,210 new cases of cancer were diagnosed and around 595,690 cancer deaths were estimated in U.S. Moreover, according to the World Cancer Research Fund International (WCRFI), in 2012, around 14.1 million cancer cases were estimated worldwide, in which, around 7.4 men and 6.6 million female diagnosed. As per WCRFI, it is predicted that by 2035, world-widely around 24 million cancer cases will raise.
Moreover, according to Cancer Research UK, around 356,860 new cases of cancer were diagnosed in 2014, in which most common cancers were breast, prostate, and lung or bowel cancer. The data represent increasing incidence and prevalence of cancer globally which is further expected to fuel the demand for cancer profiling.
Rising awareness of cancer by many organization and foundations at local, state and global level include Cancer Preventive Program by WHO, National Cancer Control Program, and Prevent Cancer Foundation, expected to fuel the growth of cancer profiling market in the near future.
Cancer/Tumor Profiling Market – Competitive Landscape
Some of the major key players operating in the global cancer profiling market include Proteome Sciences PLC, Life Technologies Corporation, Illumina, Inc., BioTheranostics, RiboMed Biotechnologies Inc., NeoGenomics Laboratories, Oxford Gene Technology Ltd., Genomic Health Inc., Agendia, and Oncopath Laboratories.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/cancer-profiling-market-967
In May 2019, QIAGEN, launched therascreen PIK3CA RGQ PCR Kit after it received (USFDA) regulatory approval as a companion diagnostic to aid in identifying breast cancer patients.
In May 2019, NeoGenomics Laboratories collaborated with QIAGEN to offer companion diagnostic test for HR+/HER2 for advanced breast cancer patients to detect PIK3CA mutation using QIAGEN’s therascreen PIK3CA RGQ PCR test.
In May 2018, ILLUMINA, Inc., acquired Edico Genome, a leading provider of data analysis acceleration solutions for next-generation sequencing (NGS) to accelerate genomic data analysis.
In August 2018, HTG molecular diagnostic, Inc. agreed with Oncologie Inc., where the companies have agreed to partner on the development of biomarkers associated with Oncologie’s Immuno-oncology pipeline.
In October 2016, Personal Genome Diagnostics Inc., one of the leading providers of advanced cancer genome testing products and services, launched PlasmaSELECT 64 targeted panel for pan-cancer tumor profiling. PlasmaSELECT 64 identifies clinically actionable and functionally important sequence mutations and structural alterations across multiple cancer types without the need for invasive biopsies
Cancer/Tumor Profiling Market -Taxonomy
- Next-Generation Sequencing (NGS)
- Quantitative Polymerase Chain Reaction (QPCR)
- Immunohistochemistry (IHC)
- In Situ Hybridization (ISH)
- Fluorescence In Situ Hybridization (FISH)
- Chromogenic In Situ Hybridization (CISH)
- Personalized Medicine
- Biomarker Discovery
- Others (Research Applications)
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire